Figure 1. IL-33 enhances mST2, IL-9, and PU.1 expression on T9 cells, and adoptive transfer of T9IL-33 cells improves GVHD and survival after allo-HCT. (A) Representative histogram of mST2 expression on murine CD4 and CD8 T cell subsets after 5 d of differentiation (n = 5, from five independent experiments, unpaired t test; data are shown as mean ± SEM; *, P < 0.05). (B) Representative histogram of mouse PU.1 expression in CD4 and CD8 T cell subsets after 5 d of differentiation (n = 5, from five independent experiments, unpaired t test; data are shown as mean ± SEM; *, P < 0.05; **, P < 0.01). (C) Representative plots of IL-9 and IFN-γ expression from in vitro differentiated murine cells and a bar graphs showing the frequency of IL-9– and IFN-γ expressing T cells (n = 4, from four independent experiments, unpaired t test; data are shown as mean ± SEM; *, P < 0.05; **, P < 0.01; ***, P < 0.001). (D) mST2 expression on human CD4 and CD8 T cell subsets after 7 d of differentiation (n = 4, from four independent experiments, unpaired t test; data are shown as mean ± SEM; *, P < 0.05, mean ± SEM). (E) Representative histogram of PU.1 expression in human CD4 and CD8 T cell subsets after 7 d of differentiation (n = 3, from three independent experiments unpaired t test; data are shown as mean ± SEM; *, P < 0.05; ***, P < 0.001). (F) Representative plots of IL-9 and IFN-γ expression in human T cells differentiated into T9 cells in the presence or absence of IL-33, and bar graphs showing the frequency of IL-9– and IFN-γ–expressing T cells (n = 4, from four independent experiments, unpaired t test; data are shown as mean ± SEM; *, P < 0.05; ***, P < 0.001). (G) Clinical scores of GVHD and survival curves for BALB/c mice transplanted with B6 or syngeneic BM cells and in vitro differentiated or freshly isolated syngeneic T cells (n = 12 each group, from two independent experiments unpaired t test; data are shown as mean ± SEM; ***, P < 0.001). (H) Clinical scores of GVHD and survival curves for BALB/c mice receiving B6 or syngeneic BM cells and in vitro differentiated or freshly isolated syngeneic T cells (n = 24 per group, from three independent experiments, unpaired t test; data are shown as mean ± SEM; **, P < 0.01; ***, P < 0.001). (I) Clinical scores of GVHD and survival curves for C3H.SW mice receiving B6 or syngeneic BM cells and in vitro differentiated or freshly isolated syngeneic T cells (n = 7 per group, unpaired t test; data are shown as mean ± SEM; **, P < 0.01; ***, P < 0.001). For survival by log-rank test; **, P < 0.01; ***, P < 0.001.
Figure 1.

IL-33 enhances mST2, IL-9, and PU.1 expression on T9 cells, and adoptive transfer of T9IL-33 cells improves GVHD and survival after allo-HCT. (A) Representative histogram of mST2 expression on murine CD4 and CD8 T cell subsets after 5 d of differentiation (n = 5, from five independent experiments, unpaired t test; data are shown as mean ± SEM; *, P < 0.05). (B) Representative histogram of mouse PU.1 expression in CD4 and CD8 T cell subsets after 5 d of differentiation (n = 5, from five independent experiments, unpaired t test; data are shown as mean ± SEM; *, P < 0.05; **, P < 0.01). (C) Representative plots of IL-9 and IFN-γ expression from in vitro differentiated murine cells and a bar graphs showing the frequency of IL-9– and IFN-γ expressing T cells (n = 4, from four independent experiments, unpaired t test; data are shown as mean ± SEM; *, P < 0.05; **, P < 0.01; ***, P < 0.001). (D) mST2 expression on human CD4 and CD8 T cell subsets after 7 d of differentiation (n = 4, from four independent experiments, unpaired t test; data are shown as mean ± SEM; *, P < 0.05, mean ± SEM). (E) Representative histogram of PU.1 expression in human CD4 and CD8 T cell subsets after 7 d of differentiation (n = 3, from three independent experiments unpaired t test; data are shown as mean ± SEM; *, P < 0.05; ***, P < 0.001). (F) Representative plots of IL-9 and IFN-γ expression in human T cells differentiated into T9 cells in the presence or absence of IL-33, and bar graphs showing the frequency of IL-9– and IFN-γ–expressing T cells (n = 4, from four independent experiments, unpaired t test; data are shown as mean ± SEM; *, P < 0.05; ***, P < 0.001). (G) Clinical scores of GVHD and survival curves for BALB/c mice transplanted with B6 or syngeneic BM cells and in vitro differentiated or freshly isolated syngeneic T cells (n = 12 each group, from two independent experiments unpaired t test; data are shown as mean ± SEM; ***, P < 0.001). (H) Clinical scores of GVHD and survival curves for BALB/c mice receiving B6 or syngeneic BM cells and in vitro differentiated or freshly isolated syngeneic T cells (n = 24 per group, from three independent experiments, unpaired t test; data are shown as mean ± SEM; **, P < 0.01; ***, P < 0.001). (I) Clinical scores of GVHD and survival curves for C3H.SW mice receiving B6 or syngeneic BM cells and in vitro differentiated or freshly isolated syngeneic T cells (n = 7 per group, unpaired t test; data are shown as mean ± SEM; **, P < 0.01; ***, P < 0.001). For survival by log-rank test; **, P < 0.01; ***, P < 0.001.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal